Explain the rationale for assessing HRQOL/PROs in clinical studies and for economic evaluation Introduce QALYs and utilities Explain methods of measuring and valuing HRQOL, and how these differ Introduce condition-specific utility measures including the cancer specific EORTC QLU-C10D
Economic evaluation and the policy context Model-based economic evaluation (Decision trees and Cohort Markov models) Developing a conceptual model structure and selecting the appropriate modelling technique Evaluating deceives and diagnostics, including co-dependents Extrapolation of survival data: current evidence on best practice
Economic Modelling Managed entry schemes Measuring and valuing quality of life "The Ashes" UK NICE v Aus PBAC Panel Discussion incl Q&A
Introduction to the treatment switching problem Consideration of different types of treatment switching and which should be adjusted for Introduction to the main adjustment methods, key assumptions and limitations (inverse probability of censoring weights, rank reserving structural failure time modules, two stage estimation) Discussion of how to identify an appropriate adjustment method on a case-by-case […]
Introduce the use of quality of life assessment and patient reported outcome measures in clinical studies and for economic evaluation.
Is budget impact analysis a poor cousin to health technology assessment and economic evaluation? Should we be doing better? What do different stakeholders need from these analyses to ensure health technologies are appropriately funded? Join us in a discussion of these and other budget impact issues with stakeholders across the PBAC process.
Introduction to Infectious Disease Modelling and Presentation of the Australian Covid-19 model Confirmed speakers Associate Professor Anthony Newall, UNSW Associate Professor James Woods, UNSW Dr Rob Moss, University of Melbourne